Precision Cancer Therapy in Rare Cancers

Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.

In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Conditions

• Rare Malignant Neoplasm

Interventions

DRUG

Imatinib

imatinib treatment based on molecular alterations

DRUG

Trametinib

According to biomarkers

DRUG

Dabrafenib

According to biomarkers

Sponsors & Collaborators

• Helse Stavanger HF

  collaborator OTHER_GOV

• University Hospital of North Norway

  collaborator OTHER

• StOlavs Hospital

  collaborator UNKNOWN

• Nordlandssykehuset HF

  collaborator OTHER

• Helse Nord-Trøndelag HF

  collaborator OTHER

• Sorlandet Hospital HF

  collaborator OTHER_GOV

• Møre og Romsdal Hospital Trust

  collaborator OTHER

• The Hospital of Vestfold

  collaborator OTHER

• Helse Fonna

  collaborator OTHER

• Haukeland University Hospital

  collaborator OTHER

• Sykehuset Ostfold

  collaborator OTHER

• Helse Forde

  collaborator OTHER

• Sykehuset Innlandet HF

  collaborator OTHER

• Oslo University Hospital

  lead OTHER

Principal Investigators

• Sigbjørn Smeland, MD PhD · Oslo University Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

16 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-03-20

Primary Completion

2033-11-30

Completion

2036-08-01

Countries

• Norway

Study Locations